Study of Low-Dose Paclitaxel with Pembrolizumab in Platinum-Refractory Urothelial Carcinoma

What we are studying

The purpose of this research study is to compare the effects (good and bad) of pembrolizumab given in combination with low-dose paclitaxel. The drug pembrolizumab is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells. Pembrolizumab had been approved for the treatment of melanoma and is being studied for the treatment of patients with other cancers including urothelial carcinoma. Paclitaxel is already a standard chemotherapy treatment for urothelial carcinoma. The goal of this study is to determine if paclitaxel can improve the anti-tumor activity of pembrolizumab.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Patients diagnosed with platinum-refractory metastatic urothelial cancer
  • Must have at least 1 prior chemotherapy regimen containing cisplatin or carboplatin
  • Must have adequate organ function
  • Must be able to consent to participate

What is involved

  • Physical examinations
  • Treatment with pembrolizumab
  • Blood and urine samples


Parking validation for study visits

Contact Information

Study Coordinator
Rhonda Bitting

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.